Liege, Belgium - Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the 'Transparency Law'), that it has received today a rectification concerning the transparency notification of Mr. Francois Fornieri dated January 7, 2022 and published in a press release on January 10, 20221 .
Mr. Fornieri has dropped below the legal 25% threshold on 31, December 2021, and not on December 17, 2022, following the temporary share loan related to the exercise by the Company of a put option on December 20, 2021 under the capital commitment agreement with LDA Capital Limited2 . Mr Fornieri will redeem his loaned shares after the full completion of the put option. The remaining information provided by Mr Fornieri's transparency declaration dated January 7, 2022 are correct. Mr. Fornieri held 24.94% (10,984,330 shares) of the 44,051,259 shares outstanding at the time. Before his threshold crossing, Mr. Fornieri held 25.44% of the 44,051,259 shares outstanding at the time.
The detailed transparency notifications are available on the Investors website of Mithra (investors.mithra.com). An updated overview of the Mithra's shareholders structure will be included in the corporate governance charter of Mithra, which will be made available on its website.
Contact:
Benoit Mathieu
IRO
T: +32 473 35 80 18
E: investorrelations@mithra.com
About Mithra
Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrol-based product in 2021, the contraceptive pill Estelle , Mithra is now focusing on its second product Donesta , the next-generation hormone therapy. Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormonedependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 300 staff members and is headquartered in Liege, Belgium. www.mithra.com
Important information
The contents of this announcement include statements that are, or may be deemed to be, 'forward-looking statements'. These forward-looking statements can be identified by the use of forward-looking terminology, including the words 'believes', 'estimates,' 'anticipates', 'expects', 'intends', 'may', 'will', 'plans', 'continue', 'ongoing', 'potential', 'predict', 'project', 'target', 'seek' or 'should', and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
MITHRA PHARMACEUTICALS S.A. 
